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Abstract: Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV
infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed
against HIV-1, and their effect on HIV-2 is understudied. Using a modular HIV-2 protease cassette
system, inhibition profiling assays were carried out for protease inhibitors both in enzymatic
and cell culture assays. Moreover, the treatment-associated resistance mutations (I54M, L90M)
were introduced into the modular system, and comparative inhibition assays were performed to
determine their effect on the susceptibility of the protease. Our results indicate that darunavir,
saquinavir, indinavir and lopinavir were very effective HIV-2 protease inhibitors, while tipranavir,
nelfinavir and amprenavir showed a decreased efficacy. I54M, L90M double mutation resulted in a
significant reduction in the susceptibility to most of the inhibitors with the exception of tipranavir.
To our knowledge, this modular system constitutes a novel approach in the field of HIV-2 protease
characterization and susceptibility testing.
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1. Introduction
The human immunodeficiency virus type 2 (HIV-2) is a retrovirus that most probably originated
from the simian immunodeficiency virus/sooty mangabeys in the Guinea-Bissau region during the
1940s [1]. Since its discovery, the virus had remained relatively contained in the West-African region,
with statistical data on its prevalence widely lacking. Current evidence suggests, however, that there
is an increasing trend of viral spread beyond its geographical confines, especially in Europe [2–4].
HIV-1 and HIV-2 share a similar genomic structure, variability in the genetic sequence accounts for
the presence of unique accessory genes; such as viral protein X (vpx) in HIV-2 and viral protein U
(vpu) in HIV-1, in addition to sequence and phenotypic differences between envelope proteins [5,6].
Clinically, HIV-2 differs significantly from HIV-1 in that it is much less pathogenic, and HIV-2 infected
patients are typically long-term non-progressors to AIDS [7,8]. This feature, undoubtedly, has led to
the lack of epidemiological studies on the virus, focusing on HIV-1 as the major pathogen.
Current treatment protocols suggest the use of three nucleoside reverse transcriptase inhibitors
(NRTIs) or two NRTIs plus one protease inhibitor (PI) as an initial therapeutic approach against
HIV-2 [9,10]. Recently, integrase strand transfer inhibitors have also been shown to exhibit potent
efficacy against HIV-2 [11]. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) should not be
used in the treatment of HIV-2 infection, as a result of natural polymorphisms in the HIV-2 reverse
transcriptase (RT) gene sequence, which alters the binding pocket significantly reducing the binding
of the inhibitor, thereby leading to resistance especially against first generation NNRTIs [12]. As
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protease inhibitors-based regimens constitute a major and effective part in the treatment of HIV
infected patients [13–15], it is essential to characterize their efficacy against HIV-2.
Ten protease inhibitors were initially approved by the Food and Drug Administration (FDA),
out of which nine remain in production today (Table 1). They are typically classified into first and
second generation inhibitors, with second generation inhibitors specifically designed to tackle HIV-1
resistance that quickly emerged with first generation drugs, as well as to improve the bioavailability,
dosing frequency, and minimize the side effects [16].
Table 1. HIV protease inhibitors.
Inhibitor Abbreviation Trade Name Remarks
Saquinavir SQV Invirase
Ritonavir RTV Norvir
Used as booster drug
Combination therapy
Indinavir INV Crixivan
Nelfinavir NFV Viracept
Amprenavir APV Agenerase Discontinued
Lopinavir/+Ritonavir LPV Kaletra, Aluvia
Second-generation
Fixed-dose combination therapy
Atazanavir ATV Reyataz Second-generation
Fosamprenavir FPV Telzir, Lexiva Second-generation
Tipranavir TPV Aptivus
Second-generation
Non-peptidic inhibitor
Darunavir DRV Prezista
Second-generation
Non-peptidic inhibitor
In comparison to HIV-1, few crystal structures of the viral protease (PR) in complex with the
inhibitors have been studied for HIV-2 [17]; moreover, the currently approved PIs are essentially
designed for HIV-1, and their association with the HIV-2 viral protease had not been thoroughly
characterized. To date, a limited number of studies tested the effect of protease inhibitors against
HIV-2, either in enzymatic or phenotypic susceptibility assays [18–23]. Many factors can influence the
results obtained, such as the stability and level of purity of the protease in enzymatic experiments, the
type of cells and methods used in cell culture assays, as well as the viral strain. Therefore, the use of a
standardized protocol that examines the efficacy of the inhibitor on the same viral enzyme in kinetic
and cell culture assays will greatly aid in the determination of a reliable, accurate and comparable
IC50 values. For this purpose, we have developed an HIV-2 protease modular cassette system [24],
which enables the study of the susceptibility of the viral protease to a panel of commercially available
PIs, in comparative enzymatic and cell culture experiments.
The viral protease is a homodimeric aspartyl protease, composed of two identical subunits that
are 99 amino acids each [25]. The enzyme is crucial for the viral life-cycle by processing the viral Gag
and Gag-Pro-Pol viral polyproteins, leading to the formation of mature, infection-competent virions.
The literature describes a 39%–48% homology of amino acid sequences between HIV-1 and HIV-2
proteases [26,27], and while the binding site remains highly conserved, this polymorphism alters the
specificity of the protease for certain peptide inhibitors, resulting in a decreased binding affinity and,
therefore, resistance to treatment.
Treatment-associated mutations in patients receiving PIs are common obstacles in combating
AIDS. As a consequence of amino acid substitution(s) in the substrate binding pocket or in a nearby
site, the binding affinity of the inhibitors may become substantially reduced, leading to failure
in blocking the viral protease [28–30]. Of the treatment-associated mutations observed in HIV-2
protease, I54M and L90M have been shown to be implicated in the reduced susceptibility to certain
protease inhibitors in phenotypic assays [18,20], but as far as we know, their effects have never
been characterized in association with all of the inhibitors, neither enzymatically nor in cell culture.
Evidence suggests that resistance to inhibitors may either be a natural phenomenon, as a result of
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polymorphism in the protease sequence, or may occur selectively under treatment pressure, in sites
usually comparable to those found in the HIV-1 protease [18,31,32].
The effects of I54M and L90M single mutations have already been described based on the
amprenavir complexes of HIV-1 PR and its drug resistant mutants [33], but to the best of our
knowledge, there are no structural data available for I54M and/or L90M mutants of HIV-2 PR.
Neither I54 nor L90 HIV-1 PR residues form direct contact with the inhibitor molecule. Substitution
of the wild-type amino acid by methionine (Met) introduces a longer side chain, resulting in a shift
of the main chain atoms relative to their original positions, in addition to the formation of new van
der Waals forces and hydrophobic interactions with the neighboring residues. I54M and L90M single
mutations were not found to have a disruptive effect on the secondary or tertiary structure [33].
Ile-54 is positioned in the flap region of the protease, but it is not exposed to the active site
cavity. It forms hydrophobic interactions with neighboring flap and loop residues. Substitution of
Ile to Met has been found to confer resistance to the protease against certain inhibitors in both HIV-1
and -2 [34,35]. Leu-90 on the other hand, is present in the hydrophobic core of the protease, near the
catalytic aspartate residues; but outside of the active site. Substitution of this residue with Met also
results in resistance to some inhibitors, again affecting both viruses [18,36,37]. Even though these
mutations do not occur in the active site; as already mentioned, it is thought that substitution of
the native amino acid to methionine may result in the displacement of certain amino acids, with an
overall impact of altering the pocket binding site and the stability of the dimer–inhibitor association,
leading to decreased efficacy or resistance to the inhibitor(s) [36,38].
2. Results and Discussion
2.1. In Vitro Kinetic Assays
In our in vitro analysis, following the expression, purification of the protease and
confirmation of its activity, kinetic parameters of the enzyme were then determined for both
the wild-type and double mutant protease. For the wild-type, Km = 0.012 ˘ 0.002 mM,
kcat = 0.91 ˘ 0.02 s´1, kcat/Km = 75.8 ˘ 12.7 mM´1¨ s´1, values were published previously [24]. As
for the double mutant protease, values were: Km = 0.07 ˘ 0.01 mM, kcat = 0.88 ˘ 0.09 s´1,
kcat/Km = 12.2 ˘ 2 mM´1¨ s´1. These values suggest that the mutations caused a substantial increase
of the Km value without affecting the turnover number. Inhibition profiling assays were performed
using the high-performance liquid chromatography (HPLC) method in triplicate measurements.
Assays using the wild-type HIV-2 protease showed that the majority of the inhibitors (with the
exception of nelfinavir, tipranavir and amprenavir) had a good inhibition efficacy against HIV-2
protease (Table 2).
Table 2. In vitro kinetic inhibition profiling of protease inhibitors for the wild-type and double mutant
HIV-2 protease.
Inhibitor
IC50 (nM) Ki (nM) IC50 (nM) Ki (nM) Fold Increase (Ki)
Wild-Type Double Mutant (I54M, L90M)
Lopinavir 1.18 ˘ 0.1 0.03 ˘ 0.001 2.32 ˘ 0.1 0.32 ˘ 0.02 10.6
Indinavir 1.30 ˘ 0.5 0.03 ˘ 0.02 2.60 ˘ 1.4 0.36 ˘ 0.07 12
Darunavir 1.76 ˘ 0.1 0.05 ˘ 0.005 8.14 ˘ 1.3 1.11 ˘ 0.1 22.2
Saquinavir 3.42 ˘ 0.1 0.09 ˘ 0.001 14.09 ˘ 1.7 1.93 ˘ 0.2 21.4
Atazanavir 3.34 ˘ 1 0.09 ˘ 0.03 10.93 ˘ 0.2 1.50 ˘ 0.04 16.6
Ritonavir 5.24 ˘ 3 0.12 ˘ 0.075 95.35 ˘ 17.6 13.05 ˘ 2.4 108.3
Nelfinavir 38 ˘ 10 1.01 ˘ 0.3 190 ˘ 14.5 26 ˘ 2 26
Tipranavir 50 ˘ 2 1.31 ˘ 0.56 4.80 ˘ 1.6 0.66 ˘ 0.2 0.5
Amprenavir 100 ˘ 7 2.43 ˘ 1.9 152 ˘ 9 20.8 ˘ 1.2 8.5
Data are expressed as mean values ˘ SD. Ki: Inhibition constant.
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Amprenavir, tipranavir and nelfinavir had the highest Ki values (2.4, 1.3 and 1 nM, respectively);
comparing this to a previous study [21], we found that while amprenavir was comparable, tipranavir
had a significantly higher Ki. To our knowledge, only one study analyzed the susceptibility of HIV-2
protease kinetically, we speculate that the difference observed in Ki of some inhibitors could be due
to the use of a different HIV-2 strain, a different substrate in the analysis, or perhaps the level of
purity and stability of the protease. Indinavir sulfate and lopinavir, on the other hand, had the
lowest Ki (0.03 nM), followed by darunavir and saquinavir (Ki = 0.05 and 0.09 nM, respectively).
Even though atazanavir sulfate had been known to have a variable and somewhat decreased
efficacy on different HIV-2 isolates [19,39], to our surprise, its efficacy was comparable to that of
saquinavir (Ki = 0.09 ˘ 0.03 µM). It is also worth mentioning that no difference was observed between
indinavir/atazanavir and their sulfate derivatives (data not shown).
Introduction of the double mutation I54M and L90M greatly decreased the efficacy of the
inhibitors, with the exception of tipranavir, which remained indifferent to the mutations. The highest
fold increase in Ki was observed in the case of ritonavir (>100 fold), followed by nelfinavir, darunavir
and saquinavir (>20 fold). Indinavir sulfate, atazanavir sulfate and lopinavir showed an increase in
Ki of more than 10 fold, while amprenavir increased by eight fold.
Tipranavir and darunavir are non-peptidic, sulfonamide containing protease inhibitors. In
contrast to other protease inhibitors, these molecules are characterized by their flexibility in binding
into the active site of the enzyme, giving them an advantage against other peptidomimetic inhibitors
should a mutation occur [40–42]. Perhaps the reason why we did not observe a significant increase
in Ki in case of the double mutant protease in association with tipranavir can be attributed to nature
of the drug’s structure. L90M exerts little or no effect on the susceptibility to tipranavir in HIV-1
isolates, while I54M was associated with a reduced susceptibility to the inhibitor [43]. In regards to
darunavir, it is likely that the main chain hydrogen bonds were affected by the mutations, resulting
in a decreased binding of the inhibitor as evident by the >20 fold increase in Ki.
2.2. Cell Culture Assays
Regarding the cell culture experiments (Table 3), darunavir and lopinavir were very potent
inhibitors of the wild-type HIV-2 protease (IC50 = 0.42 ˘ 0.05 and 0.15 ˘ 0.01 µM, respectively),
followed by saquinavir (IC50 = 1.3 ˘ 0.2 µM), indinavir sulfate (IC50= 1.4 ˘ 0.3 µM) and nelfinavir
(IC50= 2.7 ˘ 0.9). Tipranavir had an IC50 of 3.79 ˘ 0.6 µM, and the IC50 of atazanavir sulfate was
5.9 ˘ 0.5 µM.
Table 3. Inhibition profiling in cell culture using the wild-type and HIV-2 vectors harboring the
double mutation.
Inhibitor IC50 (µM) IC50 (µM) Fold IncreaseWild-Type Double Mutant (I54M, L90M)
Lopinavir 0.1 ˘ 0.01 3.1 ˘ 1.1 20.6
Darunavir 0.4 ˘ 0.05 18.7 ˘ 1.6 44.5
Saquinavir 1.3 ˘ 0.2 3.5 ˘ 1.2 2.7
Indinavir sulfate 1.4 ˘ 0.3 16.5 ˘ 2.1 11.7
Nelfinavir 2.7 ˘ 0.9 5.1 ˘ 1.7 1.8
Tipranavir 3.7 ˘ 0.6 5.8 ˘ 1.7 1.5
Atazanavir sulfate 5.9 ˘ 0.5 28.6 ˘ 0.35 4.8
Ritonavir 7.1 ˘ 0.7 14.5 ˘ 0.3 2
Amprenavir 68.7 ˘ 9.2 >100 -
Data are expressed as mean values ˘SD. (-) Fold increase unmeasurable.
The I54M-L90M double mutation resulted in >40 fold and >20 fold increase in IC50 in case of
darunavir and lopinavir, respectively, and IC50 of indinavir sulfate increased by >10 fold. The double
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mutation resulted in a significant IC50 increase of atazanavir sulfate, nelfinavir and saquinavir. As
predicted, the double mutation did not have an effect in case of tipranavir.
Despite the dramatic decrease of ritonavir’s inhibition efficacy observed after the introduction
of the double mutation in enzymatic experiments, only a two-fold increase of IC50 was detected
in cell culture assays. Being a potent inhibitor of CYP3A, ritonavir is primarily used as a booster
drug for other PI’s that are eliminated by CYP3A metabolism. It had long been successfully used
in combination with indinavir and saquinavir, enhancing their bioavailability and potentiating their
activity [44].
In contrast to other protease inhibitors, it is important to point out the fact that nelfinavir is
metabolized mainly to nelfinavir hydroxy-tert-butylamide (M8) by the P450 enzyme complexes in the
liver; particularly CYP2C19. This bioactive metabolite had been shown to exhibit a potent antiviral
activity that is comparable to that of the parent drug [45,46]. On a similar note, ritonavir is also
biotransformed to M2 by the action of CYP3A4. This active metabolite; however, is found in low
concentration in treated human plasma, and had been found to possess a much weaker anti-viral
activity as opposed to M8 [47].
2.3. Statistical and Correlation Analysis of the Assays
Due to their unique pharmacodynamic properties, we have excluded nelfinavir and ritonavir
from our correlation analysis, given the fact that HEK 293T cell line was found to express P450 enzyme
complexes; albeit in low concentration [48,49]. Their exclusion was necessary to avoid statistical bias
in the analysis. Correlating the in vitro enzymatic assays to those performed in cell-culture yielded
a Pearson’s correlation coefficient of 0.89 (p = 0.006) and 0.96 (p ď 0.001) for the wild-type and the
double mutant, respectively (Figure 1).
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Figure 1. Linear correlation analysis of IC50 obtained from in vitro enzymatic and cell culture assays
using both the wild-type and the double mutant protease. As mentioned previously nelfinavir and
ritonavir were excluded from the analysis due to their unique biotransformation properties in cell
culture. Correlation in case of the wild-type is indicated by a dotted line, while that of the double
mutant is shown by a continuous line. p values were calculated at 95% confidence intervals.
Further statistical analysis was also performed to complete the linear correlation analysis of data
showing non-normal distribution, which revealed that there are no significant differences between
the values determined by the different assays (p > 0.05) (wild-type: z = 1.35 and p = 0.22; I54M/L90M
mutant: z = 0.51 and p = 0.69). However, based on the effect size values, the magnitude of the
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difference was slightly higher in case of the wild-type (effect size value was 0.36 for the wild-type
and 0.13 for the double mutant protease).
3. Materials and Methods
3.1. The Modular System
Our modular system is composed of HIV-2CGP as a structural protein expression construct,
CRU5SINCGW; a minimal HIV-2 vector with GFP expression cassette; and pMD.G vector coding for
the envelope protein of vesicular stomatitis virus [24]. For the enzymatic assays, pET11a expression
plasmid was used to express the viral protease. HIV-2CGP and CRU5SINCGW were a kind gift from
Joseph P. Dougherty at the Robert Wood Johnson Medical School (New Brunswick, NJ, USA) [50].
HIV-2CGP was modified to include unique restriction sites (AgeI and AfeI) at 51 and 31 of the
protease coding region, respectively. These silent mutations were engineered to be 8 amino acids
apart from the ends of the protease coding sequence, to allow for the interchange of the protease
coding segment between the cell culture CGP vector and the in vitro pET11a expression plasmid as
described previously [24].
3.2. In Vitro Protease Expression and Purification
The protease ligated into pET11a was expressed in a culture of E. coli BL21 (DE3) cells
(Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA). After the disruption of cells by
sonication, the protease was then isolated from the inclusion bodies using multiple centrifugation
steps in accordance with an HIV protease expression protocol [51]. Thereafter, the protease was
purified using reversed-phase high-performance liquid chromatography (RP-HPLC) with the aid
of an ÄKTA purifier (Amersham Pharmacia Biotech, Uppsala, Sweden), using a POROS 20 R2
(PE Biosystems, PerSeptive Biosystems, Framingham, MA, USA) C18 column [24].
3.3. Enzymatic Assays
Following the expression and purification of the protease, its stability and folding were
characterized, and the activity was then determined using an oligopeptide substrate representing
the protease/reverse transcriptase cleavage site in HIV-2 [24].
Serial dilutions were prepared from the inhibitors using dimethyl sulfoxide (DMSO) in
concentrations ranging from 10 nM to 50 µM. The catalytic reactions contained 10 µL buffer E (0.5 M
phosphate, 10 mM DTT, 4 M NaCl, 10% glycerol, pH 5.6), 4.8 µL substrate, 5 µL purified protease
and 0.2 µL inhibitor in DMSO or DMSO alone (control), followed by incubation at 37 ˝C for 1 h.
The concentration of the protease was adjusted to achieve less than 20% substrate hydrolysis. After
incubation at 37 ˝C for 1 h, the reactions were terminated by the addition of 180 µL 1% trifluoroacetic
acid (TFA); thereafter, HPLC measurements were used to determine the inhibitor’s IC50 by measuring
the decrease in substrate hydrolysis. The inhibitory constant Ki was then calculated from IC50 using
the formula Ki = (IC50 ´ E/2)/(S/Km + 1), in which E is the active enzyme concentration, S is the
substrate concentration and Km is the Michaelis constant.
3.4. The Double Mutant Protease
An HIV-2 protease coding sequence identical to the wild-type, yet harboring the I54M and L90M
mutations (A162G, C268A) was synthesized and ligated into pET11a expression plasmid utilizing
GenScript services (GenScript USA Inc., Piscataway, NJ, USA). The protease sequence was verified
by sequencing and restriction analysis. AgeI and AfeI endonucleases were then used to restrict the
sequence for subsequent ligation into the CGP vector for cell culture experiments.
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3.5. Cell Culture Assays
In accordance with an HIV-1 transfection protocol [52], 293T human embryonic kidney cells
(Invitrogen) were seeded in T75 flask in 15 mL Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), 1% glutamine
and 1% penicillin-streptomycin. The day before the transfection, cells were passaged in order to
achieve 70% confluency the next day. At 70% confluency (5–6 ˆ 106 cells/mL), a total of 45 µg
plasmid DNA was used for the transfection of cells using Polyethylenimine. Cells were then incubated
at 37 ˝C, 5% CO2 in 5 mL 1% FBS containing DMEM without antibiotics. After 5–6 h, cells were split
and transferred into a 96-well plate containing serial dilutions of the inhibitor ranging from 3.2 nM
to 100 µM in a total volume of 200 µL DMEM/well, supplemented with 10% FBS, 1% glutamine
and 1% penicillin-streptomycin. After 3 days incubation at 37 ˝C, the virus-containing medium was
collected from the wells, briefly centrifuged to remove cellular debris, and 10 µL samples were taken
from each corresponding well. Reverse transcriptase colorimetric assay (catalog No. 11468120910;
Roche Applied Science, Mannheim, Germany) was then used to determine the IC50 values from
triplicate measurements. This ELISA based method quantitatively determines RT activity in cell
culture. In order to get accurate results using the colorimetric assay, a slight modification to the
manufacturer’s protocol was needed; the incubation of samples with the reaction mixture was carried
out for 17–18 h to allow for sufficient detection and quantification of reverse transcriptase.
3.6. Protease Inhibitors
The protease inhibitors darunavir, saquinavir, lopinavir, tipranavir, indinavir sulfate and
atazanavir sulfate were obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH (Germantown, MD, USA). Ritonavir was obtained from Abbott laboratories (Irving,
TX, USA), nelfinavir from Agouron, indinavir from MERCK & CO (Keilworth, NJ, USA), atazanavir
from Bristol-Myers Squibb (New York, NY, USA), and amprenavir from Vertex Pharmaceuticals Inc
(Boston, MA, USA).
3.7. Statistical Analysis
Normal distribution of the data was tested with the Shapiro–Wilk test. Differences of the IC50
values obtained from in vitro enzymatic and cell culture assays were calculated for both enzymes. The
datasets did not follow the normal distribution; thus, the non-parametric Wilcoxon-test was applied.
The null hypothesis (H0) was that IC50 values obtained had the same mean rank, and the alternative
hypothesis (H1) was that the mean ranks of the IC50 values differed according to the determination
method used, using a type I error of 0.05. Due to the small sample size, the Monte-Carlo permutation
(based on 99,999 random assignments) were applied to control the asymptotic probability value of
the tests [53,54]. Effect size quantifies the size of the difference between two groups of data (i.e., data
obtained by enzymatic and cell culture assays) in a standardized and comparable form. It ranges from
´1 to +1, where 0 means that the methods have no effect on the IC50 values; values approaching ´1
or +1 indicate larger magnitude [55,56]. Statistical tests were performed with PAST 3.09 software [57].
4. Conclusions
In conclusion, we believe this to be the first study to analyze the susceptibility of HIV-2 to
a complete panel of protease inhibitors using combined in vitro enzymatic and cell culture-based
inhibition profiling. Analyzing results obtained from both assays, we can safely conclude that
lopinavir, darunavir, indinavir sulfate and saquinavir are very potent HIV-2 protease inhibitors, as
evident from the low Ki and IC50 values calculated. Tipranavir, nelfinavir and atazanavir sulfate, on
the other hand, showed a significantly lower efficacy when compared to the others. Furthermore,
amprenavir failed to potently inhibit HIV-2 protease, especially in cell culture experiments.
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A major limitation of studies on protease inhibitors is the variability in results obtained. The
values obtained from our cell culture assays were significantly higher than those obtained from other
studies on HIV-2 [18–20]; as mentioned earlier, the type of assay used and cell culture as well as
the viral strain under examination can greatly influence the results. This variability in results serve
as hindrance to the analysis in determining the efficacy of protease inhibitors in regards to HIV-2;
therefore, our aim was to assay for all of the currently marketed protease inhibitors using the same
HIV-2 protease coding region in comparative in vitro kinetic and cell culture assays. We hope that this
methodology, as well as the results obtained from our experiments may help tailor the use of protease
inhibitors in HIV-2 infected patients.
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